Equity Profile

AZN

AstraZeneca PLC

Health CarePharmaceuticals$244.0B

Feb10Tue

Pre-Earnings Brief

UpcomingQ4-2025Pre-Market9:00 AM EST

Company Snapshot

AstraZeneca PLC (AZN) is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Operating in the health care sector, AstraZeneca plays a crucial role in addressing various medical needs, particularly in oncology, cardiovascular, and respiratory diseases.

Key Metrics to Watch

Revenue Growth

Understanding revenue growth is essential to gauge the company's market performance and demand for its products.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and financial health, influencing investor sentiment.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

AZN Q4-2025 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+72.85%

Avg Stock Reaction

-1.24%

Last Quarter Recap

In the last quarter, AstraZeneca continued to focus on expanding its product offerings and advancing its drug pipeline. The company has seen mixed results in terms of market reception and revenue growth.

Management Promises & Guidance

Commitment to advancing key oncology products.
Focus on expanding into emerging markets.
Continued investment in research and development.

Expectations

Wall Street Expectations

Overall, Wall Street appears cautiously optimistic about AstraZeneca's upcoming earnings, given its strong historical performance. However, uncertainties in the pharmaceutical sector may temper expectations.

Bull Case

If AstraZeneca can report strong EPS and revenue growth, it could reaffirm its market position and boost investor confidence, leading to a positive stock reaction.

Bear Case

Conversely, if the earnings report reveals disappointing results or setbacks in its drug pipeline, it could lead to a decline in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS and how does it compare to previous quarters?

EPS is a critical measure of profitability, and any significant deviation from expectations could impact stock performance.

What updates will be provided on the drug pipeline, particularly in oncology?

Progress in the drug pipeline can influence future revenue and investor confidence, making it a focal point for the market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of AstraZeneca's recent drug approvals, which could drive significant revenue growth this quarter.

Supporting Evidence

Recent approvals in oncology could lead to higher than expected sales.

The company's focus on emerging markets may not be fully reflected in current forecasts.

Options pricing suggests a higher expected move than historical averages, indicating potential for surprises.

Key Risk

If drug sales exceed expectations, it could significantly alter the current market outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around AstraZeneca's ability to sustain growth and manage its drug pipeline effectively.

Bull Confirmed If

A reported EPS growth of over 20% year-over-year would confirm the bull case.

Bear Confirmed If

An EPS decline or negative updates on the drug pipeline would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5%

Historical Avg

±4.2%

Pricing rich

The options market is pricing in a 5% move, suggesting that traders expect some volatility around the earnings report.

Options are pricing ±5.0% while AZN has averaged ±4.2% over the last 8 prints — setup is pricing rich.

Detail

30d HV

24.6%

Calls (21K)P/C Ratio: 0.36Puts (22K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If AstraZeneca beats expectations, history suggests a potential average stock move of +1.01%, confirming strong market confidence.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with an average move of -1.06% historically following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of new oncology drugs.
2Any changes in guidance regarding revenue growth.
3Details on market expansion strategies.
4Insights into R&D investments and their expected outcomes.
5Management's outlook on competitive pressures in the pharmaceutical sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ORIX Corporation

Company Snapshot

Key Metrics to Watch

Revenue Growth

Understanding revenue growth is essential to gauge the company's market performance and demand for its products.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of a company's profitability and financial health, influencing investor sentiment.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

AZN Q4-2025 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+72.85%

Avg Stock Reaction

-1.24%

Last Quarter Recap

Management Promises & Guidance

Commitment to advancing key oncology products.
Focus on expanding into emerging markets.
Continued investment in research and development.

Expectations

Wall Street Expectations

Bull Case

If AstraZeneca can report strong EPS and revenue growth, it could reaffirm its market position and boost investor confidence, leading to a positive stock reaction.

Bear Case

Conversely, if the earnings report reveals disappointing results or setbacks in its drug pipeline, it could lead to a decline in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS and how does it compare to previous quarters?

EPS is a critical measure of profitability, and any significant deviation from expectations could impact stock performance.

What updates will be provided on the drug pipeline, particularly in oncology?

Progress in the drug pipeline can influence future revenue and investor confidence, making it a focal point for the market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of AstraZeneca's recent drug approvals, which could drive significant revenue growth this quarter.

Supporting Evidence

Recent approvals in oncology could lead to higher than expected sales.

The company's focus on emerging markets may not be fully reflected in current forecasts.

Options pricing suggests a higher expected move than historical averages, indicating potential for surprises.

Key Risk

If drug sales exceed expectations, it could significantly alter the current market outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around AstraZeneca's ability to sustain growth and manage its drug pipeline effectively.

Bull Confirmed If

A reported EPS growth of over 20% year-over-year would confirm the bull case.

Bear Confirmed If

An EPS decline or negative updates on the drug pipeline would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±5%

Historical Avg

±4.2%

Pricing rich

The options market is pricing in a 5% move, suggesting that traders expect some volatility around the earnings report.

Options are pricing ±5.0% while AZN has averaged ±4.2% over the last 8 prints — setup is pricing rich.

Detail

30d HV

24.6%

Calls (21K)P/C Ratio: 0.36Puts (22K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If AstraZeneca beats expectations, history suggests a potential average stock move of +1.01%, confirming strong market confidence.

In-Line / Cautious

If results are in line with expectations, the stock may see muted reactions as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with an average move of -1.06% historically following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of new oncology drugs.
2Any changes in guidance regarding revenue growth.
3Details on market expansion strategies.
4Insights into R&D investments and their expected outcomes.
5Management's outlook on competitive pressures in the pharmaceutical sector.